Hanmi Pharma to move up launch of anti-obesity drug

The company will release the anti-obesity drug candidate efpeglenatide in H2 2026, earlier than initially planned

The headquarters of Hanmi Pharmaceutical 
The headquarters of Hanmi Pharmaceutical 
Young-Ae Lee 1
2024-11-21 16:49:57 0ae@hankyung.com
Bio & Pharma

South Korea’s Hanmi Pharmaceutical Co. announced on Thursday the launch of its anti-obesity drug candidate efpeglenatide has been rescheduled to the second half of 2026, earlier than originally planned.

The company has outlined a mid-to-long-term strategy to grow the product into a blockbuster drug with annual domestic sales 100 billion won ($71.5 million).

Efpeglenatide, which has completed patient recruitment for Phase 3 clinical trials, is being developed as a treatment for overweight individuals and those with stage 1 obesity.

Hanmi Pharmaceutical stated that the drug is expected to offer weight-loss effects comparable to Wegovy, a leading GLP-1 obesity treatment while providing superior cardiovascular and kidney protection compared to other GLP-1-based therapies.

Utilizing Hanmi Pharmaceutical's Lapscovery platform technology, efpeglenatide employs a slow absorption mechanism, allowing the drug to be gradually released in the body, thereby reducing gastrointestinal side effects commonly associated with GLP-1 medications.

The company is also developing a "first-in-Korea digital combination drug" that integrates efpeglenatide with a digital therapeutic component.

This innovation is designed to provide personalized obesity management solutions, including dietary and exercise plans tailored to individual patient goals.

Write to Young-Ae Lee at 0ae@hankyung.com
#Hanmi Pharmaceutical #GLP-1 #efpeglenatide #Wegovy #weight-loss effects

NPS signals more say in Hanmi Pharmaceutical's family feud

NPS signals more say in Hanmi Pharmaceutical's family feud

National Pension Fund's headquarters in Jeonju, North Jeolla Province South Korea’s National Pension Service is indicating more active involvement in the management of Hanmi Pharmaceutical Group embroiled in a years-long family feud over management control after changing the purpose of it

Hanmi Pharma’s Phase 3 trials for anti-obesity medicine approved

Hanmi Pharma’s Phase 3 trials for anti-obesity medicine approved

South Korea’s Hanmi Pharmaceutical Co. on Monday said the Ministry of Food and Drug Safety approved Phase 3 clinical trials for the company’s exclusive efpeglenatide, a glucagon-like peptide 1 (GLP-1) receptor agonist candidate for treating obesity and diabetes.  Efpeglenati

Hanmi Pharmaceutical reports record-high revenue in 2022

Hanmi Pharmaceutical reports record-high revenue in 2022

South Korea's Hanmi Pharmaceutical Co. last year saw record-high performance thanks to its self-developed drugs, surpassing its previous best year of 2015, when half of sales came from technology export fees for new drug candidates.Considered a prestigious brand of incrementally modified drugs

FDA to review Hanmi Pharmaceutical’s Rolontis for marketing approval

FDA to review Hanmi Pharmaceutical’s Rolontis for marketing approval

Rolontis, a neutropenia agent developed by Hanmi Pharmaceutical The US Food and Drug Administration has begun reviewing a medicine developed by South Korea’s Hanmi Pharmaceutical Co. for marketing authorization of the white blood cell disease treatment.The FDA will complete its review of

(* comment hide *}